156 results on '"Houssel-Debry P."'
Search Results
2. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis
- Author
-
François Villeret, Sébastien Dharancy, Domitille Erard, Armand Abergel, Louise Barbier, Camille Besch, Olivier Boillot, Karim Boudjema, Audrey Coilly, Filomena Conti, Christophe Corpechot, Christophe Duvoux, François Faitot, Stéphanie Faure, Claire Francoz, Emiliano Giostra, Jean Gugenheim, Jean Hardwigsen, Marie-Noëlle Hilleret, Jean-Baptiste Hiriart, Pauline Houssel-Debry, Nassim Kamar, Guillaume Lassailly, Marianne Latournerie, Georges-Philippe Pageaux, Didier Samuel, Claire Vanlemmens, Faouzi Saliba, and Jérôme Dumortier
- Subjects
liver transplantation ,NASH ,metabolic syndrome ,NAFLD recurrence ,Bariatric surgery ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it. Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies. Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT
- Published
- 2023
- Full Text
- View/download PDF
3. AFP score and metroticket 2.0 perform similarly and could be used in a 'within-ALL' clinical decision tool
- Author
-
Federico Piñero, Charlotte Costentin, Helena Degroote, Andrea Notarpaolo, Ilka FSF. Boin, Karim Boudjema, Cinzia Baccaro, Aline Chagas, Philippe Bachellier, Giuseppe Maria Ettorre, Jaime Poniachik, Fabrice Muscari, Fabrizio Dibenedetto, Sergio Hoyos Duque, Ephrem Salame, Umberto Cillo, Sebastián Marciano, Claire Vanlemmens, Stefano Fagiuoli, Flair Carrilho, Daniel Cherqui, Patrizia Burra, Hans Van Vlierberghe, Quirino Lai, Marcelo Silva, Fernando Rubinstein, Christophe Duvoux, Filomena Conti, Olivier Scatton, Pierre Henri Bernard, Claire Francoz, Francois Durand, Sébastien Dharancy, Marie-lorraine Woehl, Alexis Laurent, Sylvie Radenne, Jérôme Dumortier, Armand Abergel, Louise Barbier, Pauline Houssel-Debry, Georges Philippe Pageaux, Laurence Chiche, Victor Deledinghen, Jean Hardwigsen, J. Gugenheim, M. altieri, Marie Noelle Hilleret, Thomas Decaens, Paulo Costa, Elaine Cristina de Ataide, Emilio Quiñones, Margarita Anders, Adriana Varón, Alina Zerega, Alejandro Soza, Martín Padilla Machaca, Diego Arufe, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Ricardo Chong Menéndez, Martín Maraschio, Luis G. Podestá, Lucas McCormack, Juan Mattera, Adrian Gadano, Jose Huygens Parente García, Giulia Magini, Lucia Miglioresi, Martina Gambato, Cecilia D’Ambrosio, Alessandro Vitale, Michele Colledan, Domenico Pinelli, Paolo Magistri, Giovanni Vennarecci, Marco Colasanti, Valerio Giannelli, Adriano Pellicelli, Callebout Eduard, Iesari Samuele, Dekervel Jeroen, Schreiber Jonas, Pirenne Jacques, Verslype Chris, Ysebaert Dirk, Michielsen Peter, Lucidi Valerio, Moreno Christophe, Detry Olivier, Delwaide Jean, Troisi Roberto, and Lerut Jan Paul
- Subjects
Prediction ,reclassification ,recurrence ,transplantation ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Two recently developed composite models, the alpha-fetoprotein (AFP) score and Metroticket 2.0, could be used to select patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation (LT). The aim of this study was to compare the predictive performance of both models and to evaluate the net risk reclassification of post-LT recurrence between them using each model’s original thresholds. Methods: This multicenter cohort study included 2,444 adult patients who underwent LT for HCC in 47 centers from Europe and Latin America. A competing risk regression analysis estimating sub-distribution hazard ratios (SHRs) and 95% CIs for recurrence was used (Fine and Gray method). Harrell’s adapted c-statistics were estimated. The net reclassification index for recurrence was compared based on each model’s original thresholds. Results: During a median follow-up of 3.8 years, there were 310 recurrences and 496 competing events (20.3%). Both models predicted recurrence, HCC survival and survival better than Milan criteria (p
- Published
- 2023
- Full Text
- View/download PDF
4. Involvement of circulating soluble HLA-G after liver transplantation in the low immunogenicity of hepatic allograft.
- Author
-
Bastien Le Floc'h, Nathalie Costet, Nicolas Vu, Pénélope Bernabeu-Gentey, Charlotte Pronier, Pauline Houssel-Debry, Karim Boudjéma, Virginie Renac, Michel Samson, and Laurence Amiot
- Subjects
Medicine ,Science - Abstract
Graft rejection is a critical risk in solid-organ transplantation. To decrease such risk, an understanding of the factors involved in low immunogenicity of liver allografts could potentially make it possible to transfer this tolerogenic property to other transplanted organs. HLA-G, a natural physiological molecule belonging to the Human Leukocyte Antigen class (HLA) Ib family that induces tolerance, is associated with fewer rejections in solid-organ transplantation. In contrast to HLA-G, HLA antigen incompatibilities between donor and recipient can lead to rejection, except in liver transplantation. We compared HLA-G plasma levels and the presence of anti-HLA antibodies before and after LT to understand the low immunogenicity of the liver. We conducted a large prospective study that included 118 patients on HLA-G plasma levels during a 12-month follow-up and compared them to the status of anti-HLA antibodies. HLA-G plasma levels were evaluated by ELISA at seven defined pre- and post-LT time points. HLA-G plasma levels were stable over time pre-LT and were not associated with patient characteristics. The level increased until the third month post-LT, before decreasing to a level comparable to that of the pre-LT period at one year of follow-up. Such evolution was independent of biological markers and immunosuppressive treatment, except with glucocorticoids. An HLA-G plasma level ≤ 50 ng/ml on day 8 after LT was significantly associated with a higher rejection risk. We also observed a higher percentage of rejection in the presence of donor specific anti-HLA antibodies (DSA) and an association between the increase in HLA-G plasma levels at three months and the absence of DSA. The low immunogenicity of liver allografts could be related to early elevated levels of HLA-G, which lead, in turn, to a decrease in anti-HLA antibodies, opening potential new therapeutic strategies using synthetic HLA-G proteins.
- Published
- 2023
- Full Text
- View/download PDF
5. Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation.
- Author
-
Mai, Hoa Le, Treilhaud, Michèle, Ben-Arye, Shani Leviatan, Yu, Hai, Perreault, Hélène, Ang, Evelyn, Trébern-Launay, Katy, Laurent, Julie, Malard-Castagnet, Stéphanie, Cesbron, Anne, Nguyen, Thi Van Ha, Brouard, Sophie, Rostaing, Lionel, Houssel-Debry, Pauline, Legendre, Christophe, Girerd, Sophie, Kessler, Michèle, Morelon, Emmanuel, Sicard, Antoine, Garrigue, Valérie, Karam, Georges, Chen, Xi, Giral, Magali, Padler-Karavani, Vered, and Soulillou, Jean Paul
- Abstract
Background:End-stage renal failure occurs in a substantial number of patients having received a nonrenal transplantation (NRT), for whom a kidney transplantation is needed. The medical strategy regarding the use of immunosuppression (IS) for a kidney graft in patients after an NRT is not well established. The prekidney grafts long-term IS advocates for a mild induction, such as using anti-IL-2R antibodies, whereas addition of new incompatibilities and anti-HLA preimmunization may suggest using stronger IS such as induction by polyclonal antithymocyte globulins (ATG). Methods:We performed Cox multivariate and propensity score analysis of our validated transplant database to study the impact of the type of induction therapy on kidney graft survival of recipients of a kidney graft after NRT. Results:We report here that kidney transplantation after NRT treated with an ATG induction has a poorer outcome (kidney and recipient survival) than that with an anti-IL-2R induction. After accounting for potential baseline differences with a multivariate Cox model, or by adjusting on a propensity score, we found that despite patients having received ATG cumulate more risk factors, ATG appears independently involved. As animal-derived biotherapeutics induce antiglycan antibodies and particularly anti-N-glycolylneuraminic acid (Neu5Gc) IgGs which may activate endothelial cells in patients and grafts, we also investigated the magnitude and the nature of the anti-Neu5Gc elicited by the induction and showed that induction was associated with a shift in anti-Neu5Gc IgG repertoire. Possible reasons and mechanisms of a deleterious ATG usage in these patients are discussed. Conclusions:Our study suggests that ATG induction after a kidney transplantation in recipients already under maintenance IS for a NRT should be used cautiously.
- Published
- 2018
6. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation
- Author
-
Charlotte Costentin, Federico Piñero, Helena Degroote, Andrea Notarpaolo, Ilka F. Boin, Karim Boudjema, Cinzia Baccaro, Luis G. Podestá, Philippe Bachellier, Giuseppe Maria Ettorre, Jaime Poniachik, Fabrice Muscari, Fabrizio Dibenedetto, Sergio Hoyos Duque, Ephrem Salame, Umberto Cillo, Sebastian Marciano, Claire Vanlemmens, Stefano Fagiuoli, Patrizia Burra, Hans Van Vlierberghe, Daniel Cherqui, Quirino Lai, Marcelo Silva, Fernando Rubinstein, Christophe Duvoux, Filomena Conti, Olivier Scatton, Pierre Henri Bernard, Claire Francoz, Francois Durand, Sébastien Dharancy, Marie-lorraine Woehl, Alexis Laurent, Sylvie Radenne, Jérôme Dumortier, Armand Abergel, Louise Barbier, Pauline Houssel-Debry, Georges Philippe Pageaux, Laurence Chiche, Victor Deledinghen, Jean Hardwigsen, J. Gugenheim, M. Altieri, Marie Noelle Hilleret, Thomas Decaens, Aline Chagas, Paulo Costa, Elaine Cristina de Ataide, Emilio Quiñones, Sebastián Marciano, Margarita Anders, Adriana Varón, Alina Zerega, Alejandro Soza, Martín Padilla Machaca, Diego Arufe, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Ricardo Chong Menéndez, Martín Maraschio, Lucas McCormack, Juan Mattera, Adrian Gadano, Ilka S.F. Fatima Boin, Jose Huygens Parente García, Flair Carrilho, Giulia Magini, Lucia Miglioresi, Martina Gambato, Fabrizio Di Benedetto, Cecilia D’Ambrosio, Alessandro Vitale, Michele Colledan, Domenico Pinelli, Paolo Magistri, Giovanni Vennarecci, Marco Colasanti, Valerio Giannelli, Adriano Pellicelli, Cizia Baccaro, Callebout Eduard, Iesari Samuele, Dekervel Jeroen, Schreiber Jonas, Pirenne Jacques, Verslype Chris, Ysebaert Dirk, Michielsen Peter, Lucidi Valerio, Moreno Christophe, Detry Olivier, Delwaide Jean, Troisi Roberto, and Lerut Jan Paul
- Subjects
Liver transplantation ,Liver cancer ,Recurrence ,Explants pathology ,Prediction ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management. Methods: Adult patients who underwent transplantation between 2000 and 2018 for HCC in 47 centres were included. A prediction model for recurrence was developed using competing-risk regression analysis in a European training cohort (TC; n = 1,359) and tested in a Latin American validation cohort (VC; n=1,085). Results: In the TC, 76.4% of patients with HCC met the Milan criteria, and 89.9% had an AFP score of ≤2 points. The recurrence risk reassessment (R3)-AFP model was designed based on variables independently associated with recurrence in the TC (with associated weights): ≥4 nodules (sub-distribution of hazard ratio [SHR] = 1.88, 1 point), size of largest nodule (3–6 cm: SHR = 1.83, 1 point; >6 cm: SHR = 5.82, 5 points), presence of microvascular invasion (MVI; SHR = 2.69, 2 points), nuclear grade >II (SHR = 1.20, 1 point), and last pre-LT AFP value (101–1,000 ng/ml: SHR = 1.57, 1 point; >1,000 ng/ml: SHR = 2.83, 2 points). Wolber’s c-index was 0.76 (95% CI 0.72–0.80), significantly superior to an R3 model without AFP (0.75; 95% CI 0.72–0.79; p = 0.01). Four 5-year recurrence risk categories were identified: very low (score = 0; 5.5%), low (1–2 points; 15.1%), high (3–6 points; 39.1%), and very high (>6 points; 73.9%). The R3-AFP score performed well in the VC (Wolber’s c-index of 0.78; 95% CI 0.73–0.83). Conclusions: The R3 score including the last pre-LT AFP value (R3-AFP score) provides a user-friendly, standardised framework to design post-LT surveillance strategies, protocols, or adjuvant therapy trials for HCC not limited to the Milan criteria. Clinical Trials Registration: NCT03775863. Lay summary: Considering discrepancies between pre-LT tumour assessment and explant are frequent, reassessing the risk of recurrence after LT is critical to further refine the management of patients with HCC. In a large and international cohort of patients who underwent transplantation for HCC, we designed and validated the R3-AFP model based on variables independently associated with recurrence post-LT (number of nodules, size of largest nodule, presence of MVI, nuclear grade, and last pre-LT AFP value). The R3-AFP model including last available pre-LT AFP value outperformed the original R3 model only based on explant features. The final R3-AFP scoring system provides a robust framework to design post-LT surveillance strategies, protocols, or adjuvant therapy trials, irrespective of criteria used to select patients with HCC for LT.
- Published
- 2022
- Full Text
- View/download PDF
7. Influence of 4 preservation solutions on ICU stay, graft and patient survival following liver transplantation
- Author
-
Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, S., Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C., Salloum, C., Chirica, M., Abba, J., Letoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Savier, E., Brustia, R., Golmard, J.-L., and Scatton, O.
- Published
- 2020
- Full Text
- View/download PDF
8. Influence de 4 solutions de préservation sur la durée de réanimation, la survie du greffon et du patient après transplantation hépatique
- Author
-
Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, S., Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C., Salloum, C., Chirica, M., Abba, J., Letoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Savier, E., Brustia, R., Golmard, J.-L., and Scatton, O.
- Published
- 2020
- Full Text
- View/download PDF
9. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry
- Author
-
Hans-Christian Pommergaard, Andreas Arendtsen Rostved, René Adam, Mauro Salizzoni, Miguel Angel Gómez Bravo, Daniel Cherqui, Paolo De Simone, Pauline Houssel-Debry, Vincenzo Mazzaferro, Olivier Soubrane, Juan Carlos García-Valdecasas, Joan Fabregat Prous, Antonio D. Pinna, John O’Grady, Vincent Karam, Christophe Duvoux, and Lau Caspar Thygesen
- Subjects
hepatocellular carcinoma ,liver transplantation ,prognosis ,propensity score calibration ,unmeasured confounding ,non-cirrhotic liver ,cirrhosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and Aims: Prognosis after liver transplantation differs between hepatocellular carcinoma (HCC) arising in cirrhotic and non-cirrhotic livers and aetiology is poorly understood. The aim was to investigate differences in mortality after liver transplantation between these patients. Methods: We included patients from the European Liver Transplant Registry transplanted due to HCC from 1990 to November 2016 and compared cirrhotic and non-cirrhotic patients using propensity score (PS) calibration of Cox regression estimates to adjust for unmeasured confounding. Results: We included 22,787 patients, of whom 96.5% had cirrhosis. In the unadjusted analysis, non-cirrhotic patients had an increased risk of overall mortality with a hazard ratio (HR) of 1.37 (95% confidence interval [CI] 1.23–1.52). However, the HR approached unity with increasing adjustment and was 1.11 (95% CI 0.99–1.25) when adjusted for unmeasured confounding. Unadjusted, non-cirrhotic patients had an increased risk of HCC-specific mortality (HR 2.62, 95% CI 2.21–3.12). After adjustment for unmeasured confounding, the risk remained significantly increased (HR 1.62, 95% CI 1.31–2.00). Conclusions: Using PS calibration, we showed that HCC in non-cirrhotic liver has similar overall mortality, but higher HCC-specific mortality. This may be a result of a more aggressive cancer form in the non-cirrhotic liver as higher mortality could not be explained by tumour characteristics or other prognostic variables.
- Published
- 2020
- Full Text
- View/download PDF
10. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
- Author
-
Lucy Meunier, Mohamed Belkacemi, George Philippe Pageaux, Sylvie Radenne, Anaïs Vallet-Pichard, Pauline Houssel-Debry, Christophe Duvoux, Danielle Botta-Fridlund, Victor de Ledinghen, Filomena Conti, Rodolphe Anty, Vincent Di Martino, Marilyne Debette-Gratien, Vincent Leroy, Theophile Gerster, Pascal Lebray, Laurent Alric, Armand Abergel, Jérôme Dumortier, Camille Besch, Helene Montialoux, Didier Samuel, Jean-Charles Duclos-Vallée, and Audrey Coilly
- Subjects
anti HCV therapy ,DAAs ,liver transplantation ,decompensated cirrhosis ,hepatocellular carcinoma ,waiting list ,Microbiology ,QR1-502 - Abstract
Background: Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the long term, data remain minimal regarding the clinical impact of viral eradication on patients listed for decompensated cirrhosis or hepatocellular carcinoma (HCC). We aimed to elucidate the clinical outcomes of patients regarding delisting and the evolution of HCC during the long-term follow-up. Methods: An observational, multicenter, retrospective analysis was carried out on prospectively collected data from HCV-positive patients treated with an interferon-free regimen while awaiting LT in 18 French hospitals. Results: A total of 179 patients were included in the study. The indication for LT was HCC in 104 (58.1%) patients and cirrhosis in 75 (41.9%) patients. The sustained virological response was 84.4% and the treatment was well tolerated. At five years, among 75 patients with cirrhosis treated for HCV, 19 (25.3%) were delisted following improvement after treatment. Predictive factors for delisting highlighted an absence of ascites, MELD score ≤ 15, and Child–Pugh score ≤ 7. No patients with refractory ascites were delisted. Among patients with HCC, 82 (78.9%) were transplanted. The drop-out rate was low (6.7%) and few recurrences of HCC after LT were observed. Conclusions: DAAs are safe and effective in patients awaiting LT for cirrhosis or HCC. A quarter of patients with cirrhosis can be delisted because of clinical improvement. Predictive factors for delisting, as a result of improvement, may assist prescribers, before initiating HCV infection therapy in the long-term perspective.
- Published
- 2022
- Full Text
- View/download PDF
11. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool
- Author
-
Piñero, F, Costentin, C, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Carrilho, F, Cherqui, D, Burra, P, Van Vlierberghe, H, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Costa, P, de Ataide, E, Quiñones, E, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Podestá, L, Mccormack, L, Mattera, J, Gadano, A, Parente García, J, Magini, G, Miglioresi, L, Gambato, M, D'Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Piñero F., Costentin C., Degroote H., Notarpaolo A., Boin I. F., Boudjema K., Baccaro C., Chagas A., Bachellier P., Ettorre G. M., Poniachik J., Muscari F., Dibenedetto F., Duque S. H., Salame E., Cillo U., Marciano S., Vanlemmens C., Fagiuoli S., Carrilho F., Cherqui D., Burra P., Van Vlierberghe H., Lai Q., Silva M., Rubinstein F., Duvoux C., Conti F., Scatton O., Bernard P. H., Francoz C., Durand F., Dharancy S., Woehl M. l., Laurent A., Radenne S., Dumortier J., Abergel A., Barbier L., Houssel-Debry P., Pageaux G. P., Chiche L., Deledinghen V., Hardwigsen J., Gugenheim J., altieri M., Hilleret M. N., Decaens T., Costa P., de Ataide E. C., Quiñones E., Anders M., Varón A., Zerega A., Soza A., Machaca M. P., Arufe D., Menéndez J., Zapata R., Vilatoba M., Muñoz L., Menéndez R. C., Maraschio M., Podestá L. G., McCormack L., Mattera J., Gadano A., Parente García J. H., Magini G., Miglioresi L., Gambato M., D'Ambrosio C., Vitale A., Colledan M., Pinelli D., Magistri P., Vennarecci G., Colasanti M., Giannelli V., Pellicelli A., Eduard C., Samuele I., Jeroen D., Jonas S., Jacques P., Chris V., Dirk Y., Peter M., Valerio L., Christophe M., Olivier D., Jean D., Roberto T., Paul L. J., Piñero, F, Costentin, C, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Carrilho, F, Cherqui, D, Burra, P, Van Vlierberghe, H, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Costa, P, de Ataide, E, Quiñones, E, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Podestá, L, Mccormack, L, Mattera, J, Gadano, A, Parente García, J, Magini, G, Miglioresi, L, Gambato, M, D'Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Piñero F., Costentin C., Degroote H., Notarpaolo A., Boin I. F., Boudjema K., Baccaro C., Chagas A., Bachellier P., Ettorre G. M., Poniachik J., Muscari F., Dibenedetto F., Duque S. H., Salame E., Cillo U., Marciano S., Vanlemmens C., Fagiuoli S., Carrilho F., Cherqui D., Burra P., Van Vlierberghe H., Lai Q., Silva M., Rubinstein F., Duvoux C., Conti F., Scatton O., Bernard P. H., Francoz C., Durand F., Dharancy S., Woehl M. l., Laurent A., Radenne S., Dumortier J., Abergel A., Barbier L., Houssel-Debry P., Pageaux G. P., Chiche L., Deledinghen V., Hardwigsen J., Gugenheim J., altieri M., Hilleret M. N., Decaens T., Costa P., de Ataide E. C., Quiñones E., Anders M., Varón A., Zerega A., Soza A., Machaca M. P., Arufe D., Menéndez J., Zapata R., Vilatoba M., Muñoz L., Menéndez R. C., Maraschio M., Podestá L. G., McCormack L., Mattera J., Gadano A., Parente García J. H., Magini G., Miglioresi L., Gambato M., D'Ambrosio C., Vitale A., Colledan M., Pinelli D., Magistri P., Vennarecci G., Colasanti M., Giannelli V., Pellicelli A., Eduard C., Samuele I., Jeroen D., Jonas S., Jacques P., Chris V., Dirk Y., Peter M., Valerio L., Christophe M., Olivier D., Jean D., Roberto T., and Paul L. J.
- Abstract
Background & Aims: Two recently developed composite models, the alpha-fetoprotein (AFP) score and Metroticket 2.0, could be used to select patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation (LT). The aim of this study was to compare the predictive performance of both models and to evaluate the net risk reclassification of post-LT recurrence between them using each model's original thresholds. Methods: This multicenter cohort study included 2,444 adult patients who underwent LT for HCC in 47 centers from Europe and Latin America. A competing risk regression analysis estimating sub-distribution hazard ratios (SHRs) and 95% CIs for recurrence was used (Fine and Gray method). Harrell's adapted c-statistics were estimated. The net reclassification index for recurrence was compared based on each model's original thresholds. Results: During a median follow-up of 3.8 years, there were 310 recurrences and 496 competing events (20.3%). Both models predicted recurrence, HCC survival and survival better than Milan criteria (p <0.0001). At last tumor reassessment before LT, c-statistics did not significantly differ between the two composite models, either as original or threshold versions, for recurrence (0.72 vs. 0.68; p = 0.06), HCC survival, and overall survival after LT. We observed predictive gaps and overlaps between the model's thresholds, and no significant gain on reclassification. Patients meeting both models (“within-ALL”) at last tumor reassessment presented the lowest 5-year cumulative incidence of HCC recurrence (7.7%; 95% CI 5.1-11.5) and higher 5-year post-LT survival (70.0%; 95% CI 64.9-74.6). Conclusions: In this multicenter cohort, Metroticket 2.0 and the AFP score demonstrated a similar ability to predict HCC recurrence post-LT. The combination of these composite models might be a promising clinical approach. Impact and implications: Composite models were recently proposed for the selection of liver transplant (LT
- Published
- 2023
12. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort
- Author
-
Barrail-Tran, Aurélie, Goldwirt, Lauriane, Gelé, Thibaut, Laforest, Claire, Lavenu, Audrey, Danjou, Hélène, Radenne, Sylvie, Leroy, Vincent, Houssel-Debry, Pauline, Duvoux, Christophe, Kamar, Nassim, De Ledinghen, Victor, Canva, Valérie, Conti, Filomena, Durand, François, D’Alteroche, Louis, Botta-Fridlund, Danielle, Moreno, Christophe, Cagnot, Carole, Samuel, Didier, Fougerou-Leurent, Claire, Pageaux, Georges-Philippe, Duclos-Vallée, Jean-Charles, Taburet, Anne-Marie, and Coilly, Audrey
- Published
- 2019
- Full Text
- View/download PDF
13. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
- Author
-
Helena Degroote, Federico Piñero, Charlotte Costentin, Andrea Notarpaolo, Ilka F. Boin, Karim Boudjema, Cinzia Baccaro, Aline Lopes Chagas, Philippe Bachellier, Giuseppe Maria Ettorre, Jaime Poniachik, Fabrice Muscari, Fabrio Di Benedetto, Sergio Hoyos Duque, Ephrem Salame, Umberto Cillo, Adrián Gadano, Claire Vanlemmens, Stefano Fagiuoli, Fernando Rubinstein, Patrizia Burra, Daniel Cherqui, Marcelo Silva, Hans Van Vlierberghe, Christophe Duvoux, Filomena Conti, Olivier Scatton, Pierre Henri Bernard, Claire Francoz, Francois Durand, Sébastien Dharancy, Marie-lorraine Woehl, Alexis Laurent, Sylvie Radenne, Jérôme Dumortier, Armand Abergel, Louise Barbier, Pauline Houssel-Debry, Georges Philippe Pageaux, Laurence Chiche, Victor Deledinghen, Jean Hardwigsen, J. Gugenheim, M. Altieri, Marie Noelle Hilleret, Thomas Decaens, Aline Chagas, Paulo Costa, Elaine Cristina de Ataide, Emilio Quiñones, Sebastián Marciano, Margarita Anders, Adriana Varón, Alina Zerega, Alejandro Soza, Martín Padilla Machaca, Diego Arufe, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Ricardo Chong Menéndez, Martín Maraschio, Luis G. Podestá, M. Fauda, A. Gonzalez Campaña, Lucas McCormack, Juan Mattera, Adrian Gadano, Ilka S.F. Fatima Boin, Jose Huygens Parente García, Flair Carrilho, Giulia Magini, Lucia Miglioresi, Martina Gambato, Fabrizio Di Benedetto, Cecilia D’Ambrosio, Alessandro Vitale, Michele Colledan, Domenico Pinelli, Paolo Magistri, Giovanni Vennarecci, Marco Colasanti, Valerio Giannelli, Adriano Pellicelli, Cizia Baccaro, Callebout Eduard, Iesari Samuele, Dekervel Jeroen, Schreiber Jonas, Pirenne Jacques, Verslype Chris, Ysebaert Dirk, Michielsen Peter, Lucidi Valerio, Moreno Christophe, Detry Olivier, Delwaide Jean, Troisi Roberto, and Lerut Jan Paul
- Subjects
Hepatocellular carcinoma ,Downstaging ,UCSF downstaging protocol ,All-comers ,Alpha-foetoprotein ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Good outcomes after liver transplantation (LT) have been reported after successfully downstaging to Milan criteria in more advanced hepatocellular carcinoma (HCC). We aimed to compare post-LT outcomes in patients receiving locoregional therapies (LRT) before LT according to Milan criteria and University of California San Francisco downstaging (UCSF-DS) protocol and ‘all-comers’. Methods: This multicentre cohort study included patients who received any LRT before LT from Europe and Latin America (2000–2018). We excluded patients with alpha-foetoprotein (AFP) above 1,000 ng/ml. Competing risk regression analysis for HCC recurrence was conducted, estimating subdistribution hazard ratios (SHRs) and corresponding 95% CIs. Results: From 2,441 LT patients, 70.1% received LRT before LT (n = 1,711). Of these, 80.6% were within Milan, 12.0% within UCSF-DS, and 7.4% all-comers. Successful downstaging was achieved in 45.2% (CI 34.8–55.8) and 38.2% (CI 25.4–52.3) of the UCSF-DS group and all-comers, respectively. The risk of recurrence was higher for all-comers (SHR 6.01 [p
- Published
- 2021
- Full Text
- View/download PDF
14. Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients.
- Author
-
Camille Tron, Jean-Baptiste Woillard, Pauline Houssel-Debry, Véronique David, Caroline Jezequel, Michel Rayar, David Balakirouchenane, Benoit Blanchet, Jean Debord, Antoine Petitcollin, Mickaël Roussel, Marie-Clémence Verdier, Eric Bellissant, and Florian Lemaitre
- Subjects
Medicine ,Science - Abstract
Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating the interplay between pharmacogenetic determinants of TAC whole blood and intracellular exposures as well as the pharmacokinetic-pharmacodynamic relationship of TAC in both compartments. Complete pharmacokinetic profiles (Predose, and 20 min, 40 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) of twice daily TAC in whole blood and peripheral blood mononuclear cells (PBMC) were collected in 32 liver transplanted patients in the first ten days post transplantation. A non-parametric population pharmacokinetic model was applied to explore TAC pharmacokinetics in blood and PBMC. Concurrently, calcineurin activity was measured in PBMC. Influence of donor and recipient genetic polymorphisms of ABCB1, CYP3A4 and CYP3A5 on TAC exposure was assessed. Recipient ABCB1 polymorphisms 1199G>A could influence TAC whole blood and intracellular exposure (p
- Published
- 2020
- Full Text
- View/download PDF
15. Localisation hépatique isolée d’une histiocytose langerhansienne : à propos d’un cas
- Author
-
Allaume, Pierre, Meneyrol, Eric, Bernard, Gontran, Houssel-Debry, Pauline, Emile, Jean-François, and Turlin, Bruno
- Abstract
L’histiocytose langerhansienne (LCH) est une maladie de physiopathologie encore incertaine, impliquant à la fois des processus inflammatoires et une prolifération clonale. Elle est observable à tout âge, bien que dix fois plus fréquente chez les enfants que chez les adultes. Une atteinte hépatique n’est pas rare, s’intégrant le plus souvent dans une maladie systémique, et considérée péjorative. Nous rapportons ici un cas d’histiocytose langerhansienne de localisation hépatique exclusive chez un patient de 74ans. Ce cas présentait une anomalie moléculaire de la voie des MAPK, BRAFN486_P490del. À travers cette observation, nous préciserons les aspects épidémiologiques et histologiques ainsi que la démarche diagnostique à effectuer devant ce type de pathologie rare.
- Published
- 2024
- Full Text
- View/download PDF
16. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial
- Author
-
Saliba, F., Duvoux, C., Gugenheim, J., Kamar, N., Dharancy, S., Salamé, E., Neau-Cransac, M., Durand, F., Houssel-Debry, P., Vanlemmens, C., Pageaux, G., Hardwigsen, J., Eyraud, D., Calmus, Y., Di Giambattista, F., Dumortier, J., and Conti, F.
- Published
- 2017
- Full Text
- View/download PDF
17. Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation
- Author
-
Hoa Le Mai, PhD, Michèle Treilhaud, MD, Shani Leviatan Ben-Arye, PhD, Hai Yu, PhD, Hélène Perreault, PhD, Evelyn Ang, PhD, Katy Trébern-Launay, PhD, Julie Laurent, PhD, Stéphanie Malard-Castagnet, PhD, Anne Cesbron, MD, Thi Van Ha Nguyen, PhD, Sophie Brouard, PhD, Lionel Rostaing, MD, Pauline Houssel-Debry, MD, Christophe Legendre, MD, Sophie Girerd, MD, Michèle Kessler, MD, Emmanuel Morelon, MD, Antoine Sicard, MD, Valérie Garrigue, MD, Georges Karam, MD, Xi Chen, PhD, Magali Giral, MD, Vered Padler-Karavani, PhD, and Jean Paul Soulillou, MD
- Subjects
Surgery ,RD1-811 - Abstract
Background. End-stage renal failure occurs in a substantial number of patients having received a nonrenal transplantation (NRT), for whom a kidney transplantation is needed. The medical strategy regarding the use of immunosuppression (IS) for a kidney graft in patients after an NRT is not well established. The prekidney grafts long-term IS advocates for a mild induction, such as using anti-IL-2R antibodies, whereas addition of new incompatibilities and anti-HLA preimmunization may suggest using stronger IS such as induction by polyclonal antithymocyte globulins (ATG). Methods. We performed Cox multivariate and propensity score analysis of our validated transplant database to study the impact of the type of induction therapy on kidney graft survival of recipients of a kidney graft after NRT. Results. We report here that kidney transplantation after NRT treated with an ATG induction has a poorer outcome (kidney and recipient survival) than that with an anti–IL-2R induction. After accounting for potential baseline differences with a multivariate Cox model, or by adjusting on a propensity score, we found that despite patients having received ATG cumulate more risk factors, ATG appears independently involved. As animal-derived biotherapeutics induce antiglycan antibodies and particularly anti–N-glycolylneuraminic acid (Neu5Gc) IgGs which may activate endothelial cells in patients and grafts, we also investigated the magnitude and the nature of the anti-Neu5Gc elicited by the induction and showed that induction was associated with a shift in anti-Neu5Gc IgG repertoire. Possible reasons and mechanisms of a deleterious ATG usage in these patients are discussed. Conclusions. Our study suggests that ATG induction after a kidney transplantation in recipients already under maintenance IS for a NRT should be used cautiously.
- Published
- 2018
- Full Text
- View/download PDF
18. Development of an organ failure score in acute liver failure for transplant selection and identification of patients at high risk of futility.
- Author
-
Francesco Figorilli, Antonella Putignano, Olivier Roux, Pauline Houssel-Debry, Claire Francoz, Catherine Paugam-Burtz, Olivier Soubrane, Banwari Agarwal, François Durand, and Rajiv Jalan
- Subjects
Medicine ,Science - Abstract
King's College Hospital criteria are currently used to select liver transplant candidates in acetaminophen-related acute liver failure (ALF). Although widely accepted, they show a poor sensitivity in predicting pre-transplant mortality and cannot predict the outcome after surgery. In this study we aimed to develop a new prognostic score that can allow patient selection for liver transplantation more appropriately and identify patients at high risk of futile transplantation.We analysed consecutive patients admitted to the Royal Free and Beaujon Hospitals between 1990 and 2015. Clinical and laboratory data at admission were collected. Predictors of 3-month mortality in the non-transplanted patients admitted to the Royal Free Hospital were used to develop the new score, which was then validated against the Beaujon cohort. The Beaujon-transplanted group was also used to assess the ability of the new score in identifying patients at high risk of transplant futility.152 patients were included of who 44 were transplanted. SOFA, CLIF-C OF and CLIF-ACLF scores were the best predictors of 3-month mortality among non-transplanted patients. CLIF-C OF score and high dosages of norepinephrine requirement were the only significant predictors of 3-month mortality in the non-transplanted patients, and therefore were included in the ALF-OFs score. In non-transplanted patients, ALF-OFs showed good performance in both exploratory (AUC = 0.89; sensitivity = 82.6%; specificity = 89.5%) and the validation cohort (AUC = 0.988; sensitivity = 100%; specificity = 92.3%). ALF-OFs score was also able to identify patients at high risk of transplant futility (AUC = 0.917; sensitivity = 100%; specificity = 79.2%).ALF-OFs is a new prognostic score in acetaminophen-related ALF that can predict both the need for liver transplant and high risk of transplant futility, improving candidate selection for liver transplantation.
- Published
- 2017
- Full Text
- View/download PDF
19. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation
- Author
-
Costentin, C, Piñero, F, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Podestá, L, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Hoyos Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Burra, P, Van Vlierberghe, H, Cherqui, D, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Chagas, A, Costa, P, Cristina de Ataide, E, Quiñones, E, Duque, S, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Mccormack, L, Mattera, J, Gadano, A, Fatima Boin, I, Parente García, J, Carrilho, F, Magini, G, Miglioresi, L, Gambato, M, Benedetto, F, D’Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Vlierberghe, H, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Costentin, Charlotte, Piñero, Federico, Degroote, Helena, Notarpaolo, Andrea, Boin, Ilka F., Boudjema, Karim, Baccaro, Cinzia, Podestá, Luis G., Bachellier, Philippe, Ettorre, Giuseppe Maria, Poniachik, Jaime, Muscari, Fabrice, Dibenedetto, Fabrizio, Hoyos Duque, Sergio, Salame, Ephrem, Cillo, Umberto, Marciano, Sebastian, Vanlemmens, Claire, Fagiuoli, Stefano, Burra, Patrizia, Van Vlierberghe, Hans, Cherqui, Daniel, Lai, Quirino, Silva, Marcelo, Rubinstein, Fernando, Duvoux, Christophe, Conti, Filomena, Scatton, Olivier, Bernard, Pierre Henri, Francoz, Claire, Durand, Francois, Dharancy, Sébastien, Woehl, Marie-lorraine., Laurent, Alexis, Radenne, Sylvie, Dumortier, Jérôme, Abergel, Armand, Barbier, Louise, Houssel-Debry, Pauline, Pageaux, Georges Philippe, Chiche, Laurence, Deledinghen, Victor, Hardwigsen, Jean, Gugenheim, J., altieri, M., Hilleret, Marie Noelle, Decaens, Thomas, Chagas, Aline, Costa, Paulo, Cristina de Ataide, Elaine, Quiñones, Emilio, Duque, Sergio Hoyos, Marciano, Sebastián, Anders, Margarita, Varón, Adriana, Zerega, Alina, Soza, Alejandro, Machaca, Martín Padilla, Arufe, Diego, Menéndez, Josemaría, Zapata, Rodrigo, Vilatoba, Mario, Muñoz, Linda, Menéndez, Ricardo Chong, Maraschio, Martín, McCormack, Lucas, Mattera, Juan, Gadano, Adrian, Fatima Boin, Ilka SF., Parente García, Jose Huygens, Carrilho, Flair, Magini, Giulia, Miglioresi, Lucia, Gambato, Martina, Benedetto, Fabrizio Di, D’Ambrosio, Cecilia, Vitale, Alessandro, Colledan, Michele, Pinelli, Domenico, Magistri, Paolo, Vennarecci, Giovanni, Colasanti, Marco, Giannelli, Valerio, Pellicelli, Adriano, Baccaro, Cizia, Vlierberghe, Hans Van, Eduard, Callebout, Samuele, Iesari, Jeroen, Dekervel, Jonas, Schreiber, Jacques, Pirenne, Chris, Verslype, Dirk, Ysebaert, Peter, Michielsen, Valerio, Lucidi, Christophe, Moreno, Olivier, Detry, Jean, Delwaide, Roberto, Troisi, Paul, Lerut Jan, Costentin, C, Piñero, F, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Podestá, L, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Hoyos Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Burra, P, Van Vlierberghe, H, Cherqui, D, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Chagas, A, Costa, P, Cristina de Ataide, E, Quiñones, E, Duque, S, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Mccormack, L, Mattera, J, Gadano, A, Fatima Boin, I, Parente García, J, Carrilho, F, Magini, G, Miglioresi, L, Gambato, M, Benedetto, F, D’Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Vlierberghe, H, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Costentin, Charlotte, Piñero, Federico, Degroote, Helena, Notarpaolo, Andrea, Boin, Ilka F., Boudjema, Karim, Baccaro, Cinzia, Podestá, Luis G., Bachellier, Philippe, Ettorre, Giuseppe Maria, Poniachik, Jaime, Muscari, Fabrice, Dibenedetto, Fabrizio, Hoyos Duque, Sergio, Salame, Ephrem, Cillo, Umberto, Marciano, Sebastian, Vanlemmens, Claire, Fagiuoli, Stefano, Burra, Patrizia, Van Vlierberghe, Hans, Cherqui, Daniel, Lai, Quirino, Silva, Marcelo, Rubinstein, Fernando, Duvoux, Christophe, Conti, Filomena, Scatton, Olivier, Bernard, Pierre Henri, Francoz, Claire, Durand, Francois, Dharancy, Sébastien, Woehl, Marie-lorraine., Laurent, Alexis, Radenne, Sylvie, Dumortier, Jérôme, Abergel, Armand, Barbier, Louise, Houssel-Debry, Pauline, Pageaux, Georges Philippe, Chiche, Laurence, Deledinghen, Victor, Hardwigsen, Jean, Gugenheim, J., altieri, M., Hilleret, Marie Noelle, Decaens, Thomas, Chagas, Aline, Costa, Paulo, Cristina de Ataide, Elaine, Quiñones, Emilio, Duque, Sergio Hoyos, Marciano, Sebastián, Anders, Margarita, Varón, Adriana, Zerega, Alina, Soza, Alejandro, Machaca, Martín Padilla, Arufe, Diego, Menéndez, Josemaría, Zapata, Rodrigo, Vilatoba, Mario, Muñoz, Linda, Menéndez, Ricardo Chong, Maraschio, Martín, McCormack, Lucas, Mattera, Juan, Gadano, Adrian, Fatima Boin, Ilka SF., Parente García, Jose Huygens, Carrilho, Flair, Magini, Giulia, Miglioresi, Lucia, Gambato, Martina, Benedetto, Fabrizio Di, D’Ambrosio, Cecilia, Vitale, Alessandro, Colledan, Michele, Pinelli, Domenico, Magistri, Paolo, Vennarecci, Giovanni, Colasanti, Marco, Giannelli, Valerio, Pellicelli, Adriano, Baccaro, Cizia, Vlierberghe, Hans Van, Eduard, Callebout, Samuele, Iesari, Jeroen, Dekervel, Jonas, Schreiber, Jacques, Pirenne, Chris, Verslype, Dirk, Ysebaert, Peter, Michielsen, Valerio, Lucidi, Christophe, Moreno, Olivier, Detry, Jean, Delwaide, Roberto, Troisi, and Paul, Lerut Jan
- Abstract
Background & Aims: Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management. Methods: Adult patients who underwent transplantation between 2000 and 2018 for HCC in 47 centres were included. A prediction model for recurrence was developed using competing-risk regression analysis in a European training cohort (TC; n = 1,359) and tested in a Latin American validation cohort (VC; n=1,085). Results: In the TC, 76.4% of patients with HCC met the Milan criteria, and 89.9% had an AFP score of ≤2 points. The recurrence risk reassessment (R3)-AFP model was designed based on variables independently associated with recurrence in the TC (with associated weights): ≥4 nodules (sub-distribution of hazard ratio [SHR] = 1.88, 1 point), size of largest nodule (3–6 cm: SHR = 1.83, 1 point; >6 cm: SHR = 5.82, 5 points), presence of microvascular invasion (MVI; SHR = 2.69, 2 points), nuclear grade >II (SHR = 1.20, 1 point), and last pre-LT AFP value (101–1,000 ng/ml: SHR = 1.57, 1 point; >1,000 ng/ml: SHR = 2.83, 2 points). Wolber's c-index was 0.76 (95% CI 0.72–0.80), significantly superior to an R3 model without AFP (0.75; 95% CI 0.72–0.79; p = 0.01). Four 5-year recurrence risk categories were identified: very low (score = 0; 5.5%), low (1–2 points; 15.1%), high (3–6 points; 39.1%), and very high (>6 points; 73.9%). The R3-AFP score performed well in the VC (Wolber's c-index of 0.78; 95% CI 0.73–0.83). Conclusions: The R3 score including the last pre-LT AFP value (R3-AFP score) provides a user-friendly, standardised framework to design post-LT surveillance strategies, protocols, or adjuvant therapy trials for HCC not limited to the Milan
- Published
- 2022
20. HIGH RATES OF VIROLOGICAL RESPONSE AND MAJOR CLINICAL IMPROVEMENT DURING SOFOSBUVIR AND DACLATASVIR-BASED REGIMENS FOR THE TREATMENT OF FIBROSING CHOLESTATIC HCV-RECURRENCE AFTER LIVER TRANSPLANTATION: THE ANRS CO23 CUPILT STUDY: 60
- Author
-
Leroy, V., Dumortier, J., Coilly, A., Sebagh, M., Fougerou-Leurent, L., Radenne, S., Botta, D., Durand, F., Silvain, C., Lebray, P., Houssel-Debry, P., Kamar, N., D’alteroche, L., Calmus, Y., Bertucci, I., Diallo, A., Pageaux, G. P., and Duclos-Vallée, J. C.
- Published
- 2015
21. Deciphering pharmacogenetic-whole blood/intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients
- Author
-
Tron, C., Woillard, J. B., Houssel-Debry, P., David, V., Rayar, M., Balakirouchenane, D., Debord, J., Jezequel, C., Camus, C., Roussel, M., Boudjema, K., Verdier, M. C., Bellissant, E., Lemaitre, F., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Limoges, Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
liver transplantation ,[SDV]Life Sciences [q-bio] ,pharmacodynamics ,modeling ,Tacrolimus ,pharmacogenetics - Abstract
International audience; Meeting Abstract PS-161
- Published
- 2021
22. Influence of 4 preservation solutions on ICU stay, graft and patient survival following liver transplantation
- Author
-
Savier, E., Brustia, Raffaele, Golmard, J.-L., Scatton, O., Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, Samir, Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C B, Salloum, C., Chirica, M., Abba, J., Létoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Biostatistiques [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Paul Brousse, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Université de Montpellier (UM)-CHU Saint-Eloi, Hôpital de la Timone [CHU - APHM] (TIMONE), Service de pédiatrie médicale et médecine de l'adolescent [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Henri Mondor, Centre Hospitalier Universitaire [Grenoble] (CHU), Département de chirurgie digestive et de l'urgence, CHU Grenoble-Hôpital Michallon, Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital de Rangueil, CHU Toulouse [Toulouse], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nice (CHU Nice), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Bicêtre, CHU Necker - Enfants Malades [AP-HP], Agence de la Biomédecine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
- Subjects
Liver transplantation ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery ,ComputingMilieux_MISCELLANEOUS ,Preservation solution ,Multicenter study ,Human - Abstract
International audience
- Published
- 2020
23. Influence de 4 solutions de préservation sur la durée de réanimation, la survie du greffon et du patient après transplantation hépatique
- Author
-
Savier, E., primary, Brustia, R., additional, Golmard, J.-L., additional, Scatton, O., additional, Mallet, A., additional, Cherqui, D., additional, Adam, R., additional, Ciacio, O., additional, Pittau, G., additional, Trechot, B., additional, Boudjema, K., additional, Houssel-Debry, P., additional, Merdignac, A., additional, Rayar, M., additional, Soubrane, O., additional, Dokmak, S., additional, Dondero, F., additional, Sepulveda, A., additional, Bachellier, P., additional, Addeo, P.-F., additional, Faitot, F., additional, Navarro, F., additional, Herrero, A., additional, Jaber, S., additional, Pageaux, G.-P., additional, Vaillant, J.-C., additional, Rousseau, G., additional, Siksik, J.-M., additional, Le Treut, Y.P., additional, Gregoire, E., additional, Hardwigsen, J., additional, Compagnon, P., additional, Lim, C., additional, Salloum, C., additional, Chirica, M., additional, Abba, J., additional, Letoublon, C., additional, Pruvot, F.-R., additional, Boleslawski, E., additional, Salame, E., additional, Barbier, L., additional, Mabrut, J.Y., additional, Mohkam, K., additional, Suc, B., additional, Maulat, C., additional, Chiche, L., additional, Laurent, C., additional, Jeune, F., additional, Perdigao, F., additional, Dao, T., additional, Mulliri, A., additional, Gugenheim, J., additional, Boilot, O., additional, Buc, E., additional, Branchereau, S., additional, Chardot, C., additional, and Heyd, B., additional
- Published
- 2020
- Full Text
- View/download PDF
24. Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study
- Author
-
Delacôte, Claire, Favre, Mathilde, Amrani, Medhi, Ningarhari, Massih, Lemaitre, Elise, Ntandja‐Wandji, Line Carolle, Bauvin, Pierre, Boleslawski, Emmanuel, Millet, Guillaume, Truant, Stephanie, Mathurin, Philippe, Louvet, Alexandre, Canva, Valérie, Lebuffe, Gilles, Pruvot, François René, Dharancy, Sébastien, Lassailly, Guillaume, Di Martino, Vincent, Turco, Célia, Doussot, Alexandre, Chiche, Laurence, Laurent, Christophe, Chermak, Faiza, Hiriart, Jean‐Baptiste, Buchard, Benjamin, Buc, Emmanuel, Dondero, Federica, Sepulveda, Ailton, Roux, Olivier, Francoz, Claire, Bout, Hélène, Holleville, Mathilde, Duvoux, Christophe, Jost, Paul‐Henri, Girard, Edouard, Abba, Julio, Chirica, Mircea, Decaens, Thomas, Mabrut, Jean‐Yves, Lesurtel, Mickael, Antonini, Teresa, Lebosse, Fanny, Poinsot, Domitille, Lambert, Dominique, Gregoire, Emilie, Chopinet, Sophie, Decoster, Claire, Panaro, Fabrizio, Pageaux, Georges‐Philippe, Vachiery‐Lahaye, Florence, Herrero, Astrid, Ursic‐Bedoya, José, Anty, Rodolphe, Gugenheim, Jean, Goumard, Claire, Savier, Eric, Scatton, Olivier, Mazzola, Alessandra, Mallet, Maxime, Conti, Filomena, Boudjema, Karim, Sulpice, Laurent, Bardou Jacquet, Edouard, Jezequel, Caroline, Houssel‐Debry, Pauline, Bergeat, Damien, Bachellier, Philippe, Besch, Camille, Faitot, François, Addeo, Pietro, Michard, Baptiste, Maulat, Charlotte, Muscari, Fabrice, Kamar, Nassim, Venhard, Jean‐Christophe, Salame, Ephrem, Barbier, Louise, Bucur, Petru, Tabchouri, Nicolas, Brunault, Paul, Cherqui, Daniel, Saliba, Faouzi, Coilly, Audrey, Vibert, Eric, Samuel, Didier, and Adam, René
- Abstract
Liver transplant (LT) candidates with a body mass index (BMI) over 40 kg/m2have lower access to a liver graft without clear explanation. Thus, we studied the impact of obesity on the waiting list (WL) and aimed to explore graft proposals and refusal. Data between January 2007 and December 2017 were extracted from the French prospective national database: CRISTAL. Competing risk analyses were performed to evaluate predictors of receiving LT. Competitive events were (1) death/WL removal for disease aggravation or (2) improvement. The link between grade obesity, grafts propositions, and reason for refusal was studied. 15,184 patients were analysed: 10,813 transplant, 2847 death/dropout for aggravation, 748 redirected for improvement, and 776 censored. Mortality/dropout were higher in BMI over 35 (18% vs. 14% 1 year after listing) than in other candidates. In multivariate analysis, BMI>35, age, hepatic encephalopathy, and ascites were independent predictors of death/dropout. Candidates with a BMI ≥ 35 kg/m2had reduced access to LT, without differences in graft proposals. However, grafts refusal was more frequent especially for ‘morphological incompatibility’ (14.9% vs. 12.7% p< 0.01). BMI over 35 kg/m2reduces access to LT with increased risk of dropout and mortality. Increased mortality and dropout could be due to a lower access to liver graft secondary to increased graft refusal for morphological incompatibility.
- Published
- 2022
- Full Text
- View/download PDF
25. Long term results of liver transplantation for alpha-1 antitrypsin deficiency.
- Author
-
Guillaud, Olivier, Jacquemin, Emmanuel, Couchonnal, Eduardo, Vanlemmens, Claire, Francoz, Claire, Chouik, Yasmina, Conti, Filomena, Duvoux, Christophe, Hilleret, Marie-Noëlle, Kamar, Nassim, Houssel-Debry, Pauline, Neau-Cransac, Martine, Pageaux, Georges-Philippe, Gonzales, Emmanuel, Ackermann, Oanez, Gugenheim, Jean, Lachaux, Alain, Ruiz, Mathias, Radenne, Sylvie, and Debray, Dominique
- Abstract
Liver transplantation (LT) is the therapeutic option for end-stage liver disease associated with alpha1 antitrypsin (A1AT) deficiency. The aim of the present retrospective study was to report on long-term outcomes following LT for A1AT deficiency. The medical records of 90 pediatric and adult patients transplanted between 1982 and 2017 in France and Geneva (Switzerland) were reviewed. The study population consisted of 32 adults and 58 children; median age at transplant was 13.0 years (range: 0.2–65.1), and 65 were male (72.2%). Eighty-two patients (94.8% of children and 84.4% of adults) had the PI*ZZ genotype/phenotype and eight patients (8.9%) had the Pi*SZ genotype/phenotype. Eighty-four patients (93.3%) were transplanted for end-stage liver disease and six (all Pi*ZZ adults) for HCC. Median follow-up after LT was 13.6 years (0.1–31.7). The overall cumulative patient survival rates post-transplant were 97.8% at 1 year, and 95.5%, 95.5%, 92.0%, 89.1% at 5, 10, 15, 20 years respectively. The overall cumulative graft survival rates were 92.2% at 1 year, and 89.9%, 89.9%, 84.4%, 81.5% at 5, 10, 15 and 20 years, respectively. In a representative cohort of patients having presented with end-stage-liver disease or HCC secondary to A1AT, liver transplantation offered very good patient and graft survival rates. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Guide pratique de suivi du transplanté hépatique
- Author
-
Boudjema, K., Houssel-Debry, P., Jézéquel, C., Camus, C., Rayar, M., Lakéhal, M., Jacquet, E.B., Legros, L., Uguen, T., Legue, C., Centre d'Investigation Clinique [Rennes] ( CIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
survie ,syndrome métabolique ,[ SDV ] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,cancer ,suivi ,insuffisance rénale chronique - Abstract
International audience; Si l’amélioration des techniques chirurgicales et l’immunosuppresison ont permis le développement avec succès de la transplantation d’organe solide, les complications médicales au long cours persistent et sont responsables d’un déclin de la survie dès la première année après la greffe. Les complications liées au greffon (rejet, récidive de la maladie initiale, thrombose vasculaire), tumorales (cancer de novo ou récidive), cardiovasculaires, infectieuses et rénales sont les principales causes de décès après transplantation hépatique. La prévention, le diagnostic et le management de ces complications restent un véritable défi pour tout praticien prenant en charge ces patients. Une meilleure gestion des facteurs tels que le diabète, la dyslipidémie, l’hypertension artérielle et l’insuffisance rénale, peut avoir une incidence sur la mortalité à long terme. Un suivi standardisé associé à un dépistage organisé des complications médicales et chirurgicales sont donc indispensables afin d’adapter précocement la prise en charge et ainsi améliorer la survie après la greffe.
- Published
- 2018
27. Therapeutic anticoagulation after liver transplantation is not useful among patients with pre‐transplant Yerdel‐grade I/II portal vein thrombosis: A two‐center retrospective study
- Author
-
Bos, Isabel, Blondeau, Marc, Wouters, Dune, Camus, Christophe, Houssel‐Debry, Pauline, van der Plas, Willemijn S., Nieuwenhuis, Lianne M., Bardou‐Jacquet, Edouard, Lisman, Ton, de Meijer, Vincent E., Porte, Robert J., and Rayar, Michel
- Abstract
Portal vein thrombosis (PVT) is no longer a contraindication for liver transplantation (LT). While therapeutic anticoagulation (tAC) is recommended during the waiting period, there is no evidence for its usefulness in the prevention of PVT recurrence after LT.
- Published
- 2021
- Full Text
- View/download PDF
28. High intrapatient variability of tacrolimus exposure is associated with poorer outcomes after liver transplantation
- Author
-
Tron, Camille, Rayar, M., Jezequel, C., Petitcollin, A., Houssel-Debry, P., Camus, C., Verdier, M., Sulpice, L., Bellissant, E., Boudjema, K., Lemaître, F., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Fonction, structure et inactivation d'ARN bactériens, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Tron, Camille, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2017
29. Achieving SVR Does Not Prevent From Fibrosis Progession In Patients With FCH Results From A Large French Prospective Multicentric ANRS CO23 Cupilt Cohort
- Author
-
Sebagh, M., Fougerou-Leurent, C., Pageaux, G. P., Leroy, V., Dumortier, J., Radenne, S., Sylvain, C., Lebray, P., Houssel-Debry, P., Cagnot, C., Rossignol, E., Danjou, H., Veislinger, A., Didier Samuel, Duclos-Vallee, J. C., Coilly, A., AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lapeyronie [Montpellier] (CHU), Service d'hépato-gastroentérologie [CHU Grenoble Alpes], Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), CHU de Lyon, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service d'hépatogastroentérologie [Hôpital de la Croix-Rousse, Hospices Civils de Lyon], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Poitiers (CHU Poitiers), CHU Pontchaillou [Rennes], Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11), DHU Hepatinov, Novartis, Astellas, Roche, MSD, GSK, Gilead, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire [Grenoble] (CHU)
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2017
30. Characteristics, management, and outcome of tuberculosis after liver transplant: A case series and literature review
- Author
-
Nguyen Van, Rémi, Houssel-Debry, Pauline, Erard, Domitille, Dumortier, Jérôme, Pouvaret, Anne, Bergez, Guillaume, Danion, François, Surgers, Laure, Le Moing, Vincent, Kamar, Nassim, Lanternier, Fanny, and Tattevin, Pierre
- Abstract
•Tuberculosis is a severe disease in liver transplant recipients, difficult to diagnose and difficult to treat.•As in other immunocompromised populations, most patients in this case series (20/23, 87%), had extra-pulmonary tuberculosis.•Median time from liver transplant to tuberculosis diagnosis was 10 months [5–40.5]; median time from first symptoms to diagnosis was 38 days [26–60]•Even though most patients had pre-transplant risk factors for tuberculosis, screening by IFN-gamma release assay was performed in only three patients.
- Published
- 2024
- Full Text
- View/download PDF
31. P217 Usefulness of systematic liver biopsy during a surgery for inflammatory bowel disease for the diagnosis of primary sclerosing cholangitis
- Author
-
Miard, C, primary, Desfourneaux, V, additional, Dewitte, M, additional, Houssel-Debry, P, additional, Bendavid, C, additional, Harnoy, Y, additional, Siproudhis, L, additional, and Bouguen, G, additional
- Published
- 2018
- Full Text
- View/download PDF
32. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study
- Author
-
Dumortier, Jerome, Leroy, V., Duvoux, C., Lédinghen, V., Francoz, C., Houssel-Debry, P., Radenne, S., d'Alteroche, L., Fougerou-Leurent, C., Canva, V., Martino, V., Conti, F., Kamar, Nassim, Moreno, C., Lebray, P., Tran, A., Besch, C., Diallo, A., Rohel, A., Rossignol, E., Abergel, A., Botta-Fridlund, D., Coilly, A., Samuel, D., Duclos-Vallée, J.-C., Pageaux, G.-P., Département d'hépatologie, Hospices Civils de Lyon (HCL), Epidémiologie pronostique des cancers et affections graves, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Services de Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Service de Transplantation, Centre Hospitalier Universitaire de Strasbourg, Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), Unité de la recherche fondamentale et clinique sur l' hépatite virale, France Recherche Nord & Sud Asdi-VIH Hépatites, Agence Nationale de Recherche sur le Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Image Science for Interventional Techniques (ISIT), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Centre National de la Recherche Scientifique (CNRS), Service d'hépato-gastroentérologie, Hôpital de la Conception, AP-HM, Marseille, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Paul Brousse, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), National Agency for Research on Acquired Immune Deficiency Syndrome and Viral Hepatitis, Agence Nationale de Recherche sur le Sida, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11), Université de Montpellier (UM)-CHU Saint-Eloi, Jonchère, Laurent, and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV] Life Sciences [q-bio] ,hepatitis C virus ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,treatment ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,[SDV]Life Sciences [q-bio] ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,severe fibrosis (METAVIR F3/F4) ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,sofosbuvir-based ,transplantation - Abstract
International audience; Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrhosis and, therefore, graft failure and retransplantation or death. The aim of the present study was to assess efficacy and tolerance of sofosbuvir (SOF)–based regimens for the treatment of HCV recurrence in patients with severe fibrosis after LT. The Compassionate Use of Protease Inhibitors in Viral C Liver Transplantation (CULPIT) study is a prospective multicenter cohort including patients with HCV recurrence following LT treated with second generation direct antivirals. The present study focused on patients included between October 2013 and November 2014 and diagnosed with HCV recurrence and liver graft extensive fibrosis (METAVIR F3/F4). A SOF-based regimen was administered to 125 patients fulfilling inclusion criteria. The median delay from LT was 95.9 ± 69.6 months. The characteristics of patients were as follows: mean age, 59.4 ± 9.0 years; 78.4% male; infected by HCV genotype 1: 78.2%, mean HCV RNA: 6.1 ± 1.0 log10 IU/mL. Eighty patients had failed previous post-LT antiviral therapy (64.0%) including triple therapy with first generation protease inhibitors in 19 (15.2%) patients. The main combination regimen was SOF/daclatasvir (73.6%). Ribavirin was used in 60 patients. Sustained virological response 12 weeks after treatment was 92.8% (on an intention-to-treat basis); 7 patients with virological failure were observed. Serious adverse events occurred in 25.6% of the patients during antiviral treatment. During antiviral treatment and follow-up, 3 patients were retransplanted and 4 patients died. In conclusion, SOF-based antiviral treatment shows very promising results in patients with HCV recurrence and severe fibrosis after LT. Liver Transplantation 22 1367–1378 2016 AASLD. © 2016 by the American Association for the Study of Liver Diseases
- Published
- 2016
33. La perte de masse musculaire mesurée par le diamètre du psoas est un facteur prédictif de mortalité des patients ayant une cirrhose inscrite sur liste de transplantation hépatique
- Author
-
Huguet, A., primary, Bardou-Jacquet, E., additional, Houssel-Debry, P., additional, Latournerie, M., additional, Jezequel, C., additional, Legros, L., additional, Guyader, D., additional, and Thibault, R., additional
- Published
- 2017
- Full Text
- View/download PDF
34. Baseline serum ferritin is an independent predictive factor of mortality in patients with chronic hepatitis C after long term follow-up
- Author
-
Jezequel, C., primary, Ali, Z.B., additional, Pronier, C., additional, Rabot, A., additional, Renard, I., additional, Legros, L., additional, Uguen, T., additional, Bardou-Jacquet, E., additional, Lan, C.L., additional, Moirand, R., additional, Houssel-Debry, P., additional, Michelet, C., additional, Thibault, V., additional, and Guyader, D., additional
- Published
- 2017
- Full Text
- View/download PDF
35. Treatment and prognosis of acute severe autoimmune hepatitis
- Author
-
De Martin, E., primary, Coilly, A., additional, Houssel-Debry, P., additional, Ollivier-Hourmand, I., additional, Heurgue-Berlot, A., additional, Artru, F., additional, Barge, S., additional, Chazouilleres, O., additional, Silvain, C., additional, Duvoux, C., additional, Pageaux, G.-P., additional, Besch, C., additional, Bourlière, M., additional, Fontaine, H., additional, de Ledinghen, V., additional, Dumortier, J., additional, Conti, F., additional, Radenne, S., additional, Debette-Gratien, M., additional, Goria, O., additional, Boursier, J., additional, Peron, J.-M., additional, Durand, F., additional, Borrentain, P., additional, Potier, P., additional, Minello, A., additional, Abergel, A., additional, Perarnau, J.-M., additional, Nousbaum, J.-B., additional, Rudler, M., additional, Alric, L., additional, Anty, R., additional, Sturm, N., additional, Sebagh, M., additional, Agostini, H., additional, Samuel, D., additional, and Duclos-Vallée, J.-C., additional
- Published
- 2017
- Full Text
- View/download PDF
36. Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction
- Author
-
Elkrief, Laure, Houssel-Debry, Pauline, Ackermann, Oanez, Franchi-Abella, Stéphanie, Branchereau, Sophie, Valla, Dominique, Hillaire, Sophie, Dutheil, Danielle, Plessier, Aurélie, Hernandez-Gea, Virginia, and Bureau, Christophe
- Abstract
Chronic non cirrhotic extrahepatic portal vein obstruction (EHPVO) refers to the cavernomatous transformation of the portal vein (the so-called “portal cavernoma”) which occurs following acute thrombosis of the portal vein in the absence of recanalization. In adults, EHPVO mainly occurs following thrombosis, while in children it may be related to congenital malformations and/or neonatal umbilical venous catheterization. However, 50% of the cases of EHPVO remain idiopathic [1]. Risk factors and associated diseases should be investigated (chapter 1). Indeed, the presence of a thrombophilic alteration, in particular myeloproliferative neoplasm impacts prognosis and determine a causal treatment.
- Published
- 2020
- Full Text
- View/download PDF
37. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry
- Author
-
Pommergaard, Hans-Christian, Rostved, Andreas Arendtsen, Adam, René, Salizzoni, Mauro, Bravo, Miguel Angel Gómez, Cherqui, Daniel, De Simone, Paolo, Houssel-Debry, Pauline, Mazzaferro, Vincenzo, Soubrane, Olivier, García-Valdecasas, Juan Carlos, Prous, Joan Fabregat, Pinna, Antonio D., O’Grady, John, Karam, Vincent, Duvoux, Christophe, and Thygesen, Lau Caspar
- Abstract
Background and Aims:Prognosis after liver transplantation differs between hepatocellular carcinoma (HCC) arising in cirrhotic and non-cirrhotic livers and aetiology is poorly understood. The aim was to investigate differences in mortality after liver transplantation between these patients. Methods:We included patients from the European Liver Transplant Registry transplanted due to HCC from 1990 to November 2016 and compared cirrhotic and non-cirrhotic patients using propensity score (PS) calibration of Cox regression estimates to adjust for unmeasured confounding. Results:We included 22,787 patients, of whom 96.5% had cirrhosis. In the unadjusted analysis, non-cirrhotic patients had an increased risk of overall mortality with a hazard ratio (HR) of 1.37 (95% confidence interval [CI] 1.23–1.52). However, the HR approached unity with increasing adjustment and was 1.11 (95% CI 0.99–1.25) when adjusted for unmeasured confounding. Unadjusted, non-cirrhotic patients had an increased risk of HCC-specific mortality (HR 2.62, 95% CI 2.21–3.12). After adjustment for unmeasured confounding, the risk remained significantly increased (HR 1.62, 95% CI 1.31–2.00). Conclusions:Using PS calibration, we showed that HCC in non-cirrhotic liver has similar overall mortality, but higher HCC-specific mortality. This may be a result of a more aggressive cancer form in the non-cirrhotic liver as higher mortality could not be explained by tumour characteristics or other prognostic variables.
- Published
- 2020
- Full Text
- View/download PDF
38. Performance of B-mode ratio and 2D shear wave elastography for the detection and quantification of hepatic steatosis and fibrosis after liver transplantation
- Author
-
Dubois, Marine, Ronot, Maxime, Houssel-Debry, Pauline, Brun, Vanessa, Rayar, Michel, Auger, Magali, Beuzit, Luc, Turlin, Bruno, Aubé, Christophe, and Paisant, Anita
- Published
- 2020
- Full Text
- View/download PDF
39. OR01: A Low Transversal Psoas Muscle Thickness Assessed by Computed Tomography (CT) Scan is a Prognostic Factor in Cirrhotic Patients on Waiting-List for Liver Transplantation
- Author
-
Huguet, A., primary, Bardou Jacquet, E., additional, Houssel Debry, P., additional, Latournerie, M., additional, Jezequel, C., additional, Legros, L., additional, Guyader, D., additional, and Thibault, R., additional
- Published
- 2016
- Full Text
- View/download PDF
40. Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study
- Author
-
Houssel-Debry, P., primary, Duvoux, C., additional, Coilly, A., additional, Fougerou-Leurent, C., additional, Jezequel, C., additional, De Ledinghen, V., additional, Radenne, S., additional, Kamar, N., additional, Leroy, V., additional, Di Martino, V., additional, D’Alteroche, L., additional, Canva, V., additional, Conti, F., additional, Dumortier, J., additional, Montialoux, H., additional, Lebray, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Moreno, C., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Durand, F., additional, Abergel, A., additional, Habersetzer, F., additional, Debette-Gratien, M., additional, Rohel, A., additional, Diallo, A., additional, Rossignol, E., additional, Veislinger, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
41. Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt
- Author
-
Anty, R., primary, Coilly, A., additional, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Botta-Fridlund, D., additional, Leroy, V., additional, Durand, F., additional, Tran, A., additional, Montialoux, H., additional, Habersetzer, F., additional, Favre, G., additional, Rossignol, E., additional, Rohel, A., additional, Renault, A., additional, Dharancy, S., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
42. Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study
- Author
-
Dharancy, S., primary, Coilly, A., additional, Fougerou-Leurent, C., additional, Duvoux, C., additional, Kamar, N., additional, Leroy, V., additional, Tran, A., additional, Houssel-Debry, P., additional, Canva, V., additional, Moreno, C., additional, Conti, F., additional, Dumortier, J., additional, Di Martino, V., additional, Radenne, S., additional, De Ledinghen, V., additional, D’Alteroche, L., additional, Silvain, C., additional, Besch, C., additional, Perré, P., additional, Botta-Fridlund, D., additional, Francoz, C., additional, Habersetzer, F., additional, Montialoux, H., additional, Abergel, A., additional, Debette-Gratien, M., additional, Rohel, A., additional, Vallée, J.C.D., additional, and Pageaux, G.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
43. Safety of sofosbuvir‐based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.
- Author
-
Anty, R., Favre, G., Coilly, A., Rossignol, E., Houssel‐Debry, P., Duvoux, C., De Ledinghen, V., Di Martino, V., Leroy, V., Radenne, S., Kamar, N., Canva, V., D'Alteroche, L., Durand, F., Dumortier, J., Lebray, P., Besch, C., Tran, A., Canivet, C. M., and Botta‐Fridlund, D.
- Subjects
SOFOSBUVIR ,LIVER transplantation ,HEPATITIS C virus ,GLOMERULAR filtration rate ,NEPHROTOXICOLOGY ,MYCOPHENOLIC acid - Abstract
Summary: Background: In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir‐based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. Aim: To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. Methods: In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease–Epidemiology Collaboration (CKD‐EPI) equation. Slopes of eGFR were defined as a change in eGFR during a period divided by time. Pre‐treatment, on‐treatment and post‐treatment periods were 9 months, 3‐9 months and 4.5 months. Interactions between eGFR slopes and the pre‐treatment eGFR, use of ribavirin or mycophenolate mofetil, and stage of fibrosis were addressed. On‐treatment eGFR slopes were separated in tertiles. Pre‐ and post‐treatment eGFR slopes were compared globally and according to tertiles. Results: The post‐treatment eGFR slope was significantly better than pre‐treatment eGFR slope (+0.18 (IQR −0.76 to +1.32) vs −0.11 (IQR −1.01 to +0.73) mL/min/1.73 m
2 /month, P = 0.03) independently of the pre‐treatment eGFR (P = 0.99), ribavirin administration (P = 0.26), mycophenolate mofetil administration (P = 0.51) and stage of fibrosis (F3 and F4 vs lower stages, P = 0.18; F4 vs lower stages, P = 0.08; F4 Child‐Pugh B and C vs lower stages, P = 0.38). Tertiles of on‐treatment eGFR slopes were −1.71 (IQR −2.54 to −1.48), −0.78 (IQR −1.03 to −0.36) and +0.75 (IQR +0.28 to +1.47) mL/min/1.73 m2 /month. Pre‐ and post‐treatment eGFR slopes were not significantly different according to tertiles (respectively, P = 0.34, 0.08, 0.73). Conclusion: The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir‐based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
44. Bariatric surgery and liver transplantation, here we are now: A French nationwide retrospective study
- Author
-
Dumortier, Jérôme, Erard, Domitille, Villeret, François, Faitot, François, Duvoux, Christophe, Faure, Stéphanie, Francoz, Claire, Gugenheim, Jean, Hardwigsen, Jean, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Bello, Arnaud Del, Lassailly, Guillaume, Vanlemmens, Claire, Saliba, Faouzi, Altman, Clara, Latournerie, Marianne, Dharancy, Sébastien, and Debs, Tarek
- Abstract
At the time of the growing obesity epidemic worldwide, liver transplantation (LT) and metabolic syndrome are closely linked: non-alcohol-related fatty liver disease (NAFLD) is one of the leading indications for liver transplantation, and metabolic syndrome can also appear after liver transplantation, in relation to immunosuppressive medications and weight gain, whatever was the initial liver disease leading to the indication of LT. Therefore, the role of bariatric surgery (BS) is important due to its longer-lasting effect and efficacy. We performed a retrospective review of all 50 adult French liver transplant recipients who had a history of bariatric surgery, including 37 procedures before transplantation, and 14 after. There were three significantly different characteristics when comparing pre-and post-LT BS: patients were older (at the time of BS), presented more frequently arterial hypertension (at the time of LT), and the proportion of NAFLD as initial liver disease leading to LT was lower, in the post-LT group. Regarding pre-LT BS, in one case BS was complicated by liver failure leading to the rapid indication of LT; it was the single patient for whom the delay between BS and LT was less than 1 year; there was no patient who specifically underwent BS for the purpose of LT listing.
- Published
- 2023
- Full Text
- View/download PDF
45. P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study
- Author
-
Antonini, T.M., primary, Coilly, A., additional, Radenne, S., additional, Veislinger, A., additional, Botta-Fridlund, D., additional, Durand, F., additional, Houssel-Debry, P., additional, Kamar, N., additional, Canva, V., additional, Perre, P., additional, Bertucci, I., additional, Dumortier, J., additional, Leroy, V., additional, Samuel, D., additional, Pageaux, G.-P., additional, and Duclos-Vallee, J.-C., additional
- Published
- 2015
- Full Text
- View/download PDF
46. P0709 : Survival of patients infected by chronic hepatitis c and f0f1 fibrosis at baseline after a 15 years follow-up
- Author
-
Jézéquel, C., primary, Bardou-Jacquet, E., additional, Desille, Y., additional, Renard, I., additional, Lainé, F., additional, Lelan, C., additional, Latournerie, M., additional, Guillygomarch, A., additional, Houssel-Debry, P., additional, Moirand, R., additional, Deugnier, Y., additional, and Guyader, D., additional
- Published
- 2015
- Full Text
- View/download PDF
47. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
- Author
-
Coilly, A., primary, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Leroy, V., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Rohel, A., additional, Renault, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2015
- Full Text
- View/download PDF
48. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study
- Author
-
Dumortier, J., primary, Botta-Fridlund, D., additional, Coilly, A., additional, Leroy, V., additional, Fougerou-Leurent, C., additional, Danjou, H., additional, Radenne, S., additional, Durand, F., additional, Kamar, N., additional, di Martino, V., additional, de Ledinghen, V., additional, Houssel-Debry, P., additional, d’Alteroche, L, additional, Duvoux, C., additional, Conti, F., additional, Canva, V., additional, Diallo, A., additional, Rohel, A., additional, Duclos-Vallée, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2015
- Full Text
- View/download PDF
49. Hepatic encephalopathy post liver transplantation
- Author
-
Morandeau, Emilie, Rayer, Cassandra, Jezequel, Caroline, Guyader, Dominique, Houssel-Debry, Pauline, Bardou-Jacquet, Edouard, and Legros, Ludivine
- Published
- 2020
- Full Text
- View/download PDF
50. Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension.
- Author
-
Legros, Ludivine, Chabanne, Céline, Camus, Christophe, Fournet, Maxime, Houssel-Debry, Pauline, Latournerie, Marianne, Jezequel, Caroline, Rayar, Michel, Boudjema, Karim, Guyader, Dominique, and Bardou-Jacquet, Edouard
- Abstract
Background and aims Portopulmonary hypertension (POPH) hampers survival of patients with cirrhosis and portal hypertension and may preclude liver transplantation (LT). Management of such patients with oral pulmonary vasoactive drugs (PVD) has not been standardized. Our aim was to assess the efficacy and safety of oral PVD for management of POPH. Methods All patients treated by oral PVD (bosentan, ambrisentan, sildenafil, tadalafil) for POPH were retrospectively studied. Significant response was defined for the patients who reached the following LT eligibility criteria: mean pulmonary artery pressure (MPAP) <35 mmHg or MPAP between 35 and 50 mmHg with pulmonary vascular resistance (PVR) <250 dyn s cm −5 . Results 20 patients were followed for 38 (19–57) months. Oral PVD improved MPAP (−8 [−19, +2] mmHg), PVR (−201 [–344, –68] dyn s cm −5 ) and 6-min walk distance (+52 [−51, +112] m). Fifty-three percent of evaluable patients reached eligibility to LT criteria, of whom 5 were transplanted. Baseline MPAP > 51 mmHg and/or PVR > 536 dyn s cm −5 predicted non response to treatment. Five-years survival was 53%. No worsening of cirrhosis or serious adverse effect was recorded. Conclusion Oral pulmonary vasoactive drugs are safe in cirrhotic patients with POPH. These treatments improved hemodynamic conditions allowing patients access to liver transplantation eligibility. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.